To view the full text, please login as a subscribed user or purchase a subscription.
Click here to view the full text on ScienceDirect.
Abstract
The purpose of this study was to determine if flumazenil is absorbed from broncho-pulmonary tissue after intratracheal administration and whether therapeutically significant plasma concentrations can be obtained. Six elective surgical patients received a dose of 1.0 mg flumazenil in 10 mL saline intratracheally during general anesthesia. Blood samples were drawn for 6 hours after administration and plasma concentrations were determined by gas chromatography-mass spectrometry (GC-MS). An average peak plasma flumazenil concentration of 65.9 ± 43.1 ng/mL was attained within 1 minute after administration. No patients reported chest discomfort or dyspnea upon awakening and there were no other side effects noted. Administration of flumazenil via an endotracheal tube results in rapid attainment of therapeutic blood levels.
☆Supported in part by a merit review award from the Veterans Affairs Research Service. Flumazenil and midazolam were donated by Roche Laboratories, Nutley, NJ.
☆Dr Palmer is currently affiliated with the Toxicology Program, College of Pharmacy, University of New Mexico, Albuquerque.
